Laurus Labs Limited
All news and filings related to Laurus Labs Limited.
View all news & filings- High impact
Laurus Labs Q1 FY27: Revenue Soars 29% to ₹2,026 Cr, EBITDA Jumps 66%
Laurus Labs reported a 29% YoY revenue growth to ₹2,026 crore in Q1 FY27, driven by CDMO and Affordable Medicines segments. EBITDA surged 66% to ₹644 crore with margins at 31.8%. Net profit increased 126% to ₹368 crore. CAPEX was 19% of sales.
Read the summary - Low impact
Laurus Labs to Participate in Goldman Sachs Global Healthcare CDMO Day in Singapore
Laurus Labs will attend the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 22-24, 2026. The company will participate in in-person one-on-one and group meetings with investors. Dates are subject to change, and no UPSI will be shared.
Read the summary - Low impact
Laurus Labs to Participate in ICICI Securities Investor Meeting on Sep 17
Laurus Labs will attend a group investor meeting organized by ICICI Securities in Hyderabad on September 17, 2026. The interaction will be in-person. The company noted that the date is subject to change and no Unpublished Price Sensitive Information will be disclosed.
Read the summary - Low impact
Laurus Labs to Participate in Antique Pharma Investor Day on Sep 7, 2026
Laurus Labs will attend the Antique Pharma Investor Day on September 7, 2026, in Hyderabad. This in-person meeting is part of the company's investor outreach efforts. The date is subject to change, and no sensitive information will be disclosed.
Read the summary - Low impact
Laurus Labs to Participate in Motilal Oswal Global Investor Conference on Aug 19
Laurus Labs will attend the Motilal Oswal 22nd Annual Global Investor Conference in Mumbai on August 19, 2026. The company will participate in in-person one-on-one and group meetings with analysts and institutional investors.
Read the summary - Low impact
Laurus Labs Scores 63/100 in NSE ESG Rating for FY26
Laurus Labs received an ESG Score of 63/100 for FY26 from NSE Sustainability Ratings. The score was independently assigned by NSE Sustainability based on public data, without prior engagement from Laurus Labs. This disclosure adheres to SEBI Listing Regulations.
Read the summary - High impact
Laurus Labs Q1 FY27 Earnings Call Transcript Released
Laurus Labs released its Q1 FY27 earnings call transcript. The company reported record quarterly revenue of INR 2,026 crores (up 29%), driven by CDMO growth (INR 835 crores, up 69%) and Affordable Medicines (INR 1,156 crores, up 10%). EBITDA margins improved to 31.8%. Significant investments are being made in capacity expansion for CDMO and new modalities.
Read the summary - Low impact
Laurus Labs Allots 62,635 Shares Under ESOP Schemes
Laurus Labs allotted 62,635 equity shares to 839 employees on July 27, 2026, under its ESOP schemes. The allotment was made under the 2016, 2018, and 2021 ESOP schemes. The total paid-up capital now stands at Rs. 1,08,06,24,436.
Read the summary - Medium impact
Laurus Labs Demerger & Amalgamation Scheme Gets NCLT Hearing Date
Laurus Labs' Composite Scheme of Arrangement, involving demerger and amalgamation of subsidiaries, progresses. The NCLT has directed notice serving and set September 10, 2026, as the next hearing date for scheme consideration.
Read the summary - High impact
Laurus Labs Q1 FY27 Results: Revenue ₹2,026 Cr, Profit ₹362 Cr
Laurus Labs reported unaudited Q1 FY27 results with total revenue at ₹2,026.31 crore, up from ₹1,811.57 crore in Q4 FY26. Net profit after tax was ₹362.07 crore, a significant rise from ₹282.09 crore in Q4 FY26. EPS stood at ₹6.81.
Read the summary - Low impact
Laurus Labs Q1 FY27 Earnings Call Audio Recording Available
Laurus Labs has released the audio recording for its Q1 FY27 results conference call, which took place on July 24, 2026. The link to the recording is now available.
Read the summary - High impact
Laurus Labs Q1 FY27 Revenue Surges 29% to ₹2,026 Cr; Net Profit Jumps 126%
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Cr, up 29% YoY, and net profit of ₹368 Cr, up 126%. EBITDA rose 66% to ₹644 Cr with margins at 31.8%. CDMO revenue grew 67% to ₹870 Cr. The company in-licensed two ADCs and is investing in CAPEX for future growth.
Read the summary - High impact
Laurus Labs Q1 FY27 Revenue Surges 29% to ₹2,026 Crore, EBITDA Up 66%
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore, up 29% YoY. EBITDA increased 66% to ₹644 Crore with margins at 31.8%. CDMO revenue grew 67% to ₹870 Crore. CAPEX was ₹394 Crore (19% of sales). R&D increased 74% to ₹118 Crore. The company is investing in Advanced Biologics and has confirmed its SBTi targets.
Read the summary - Low impact
Laurus Labs: Independent Director Dr. Rajesh Koshy Chandy to Retire on July 26, 2026
Dr. Rajesh Koshy Chandy, Independent Director at Laurus Labs, will retire on July 26, 2026, upon completion of his second term. The Board of Directors noted his retirement in a meeting held on July 24, 2026.
Read the summary - High impact
Laurus Labs Q1FY27 Results: Revenue Up 15% to ₹2,035 Cr, Profit ₹362 Cr
Laurus Labs reported Q1FY27 results. Consolidated revenue increased by 15% to ₹2,035.49 crore. Profit after tax surged to ₹361.99 crore. Standalone revenue grew to ₹1,777.23 crore, with profit after tax at ₹289.96 crore. The results were approved on July 24, 2026.
Read the summary - Low impact
Laurus Labs: Certificate under SEBI Reg 74(5) for Q1FY27
Laurus Labs Limited received a certificate under SEBI Regulation 74(5) for the quarter ended June 30, 2026. The certificate from KFin Technologies Limited confirms details of securities dematerialized/rematerialized have been furnished to stock exchanges. This is a routine compliance filing.
Read the summary - Medium impact
Laurus Labs: CARE Ratings Reaffirms Long-Term 'CARE AA; Stable' Rating
Laurus Labs' bank facilities have been reaffirmed with a long-term rating of 'CARE AA; Stable' and short-term rating of 'CARE A1+' by CARE Ratings. This reaffirmation reflects sustained performance improvement in FY26, including growth in TOI and profitability.
Read the summary - Medium impact
Laurus Labs Appoints Dr. Shekhar Mande & Ms. Sutapa Banerjee as Independent Directors
Laurus Labs appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors at its 21st AGM on July 2, 2026. Both appointments are for a five-year term commencing July 2, 2026. The directors are not related to existing management.
Read the summary - Medium impact
Laurus Labs AGM Concludes: All 9 Resolutions Passed, Including Director Re-appointments and Remuneration Approvals
Laurus Labs' 21st AGM on July 2, 2026, saw all nine resolutions passed. Key approvals included audited financial statements for FY26, interim dividends of ₹0.80 and ₹1.20 per share for FY26, re-appointments of Directors Krishna Chaitanya Chava and Soumya Chava, and appointments of Independent Directors Shekhar Chintamani Mande and Sutapa Banerjee.
Read the summary - Low impact
Laurus Labs: Trading Window Closes July 1 for Q1 FY27 Results
Laurus Labs will close its trading window from July 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. The board meeting date for approving these results will be announced later.
Read the summary - Low impact
Laurus Labs Allots 3.93 Lakh Shares Under ESOPs
Laurus Labs allotted 3,93,001 equity shares on June 04, 2026, to employees exercising ESOPs. The total amount realized was ₹12.40 crore. This issuance increases the company's paid-up capital to ₹108.05 crore.
Read the summary - Low impact
Laurus Labs to Participate in Investor Conferences in June 2026
Laurus Labs will participate in investor conferences in June 2026. The company will attend the BofA Healthcare Tour on June 5, 2026, and the Macquarie Healthcare Tour on June 10, 2026, both in Hyderabad. No Unpublished Price Sensitive Information will be shared.
Read the summary - Low impact
Laurus Labs announces participation in investor conferences in May & June 2026
Laurus Labs will participate in the 360 ONE Capital (B&K) 16th Annual Investor Conference in Mumbai on May 27, 2026, and the Citi 2026 India Conference in Mumbai on June 04, 2026. The meetings will involve one-on-one and group interactions. No unpublished price-sensitive information will be shared.
Read the summary - Medium impact
Laurus Labs Included in Dow Jones Best-in-Class (DJ BIC) World Index
Laurus Labs announced its inclusion in the Dow Jones Best-in-Class (DJ BIC) World Index, recognizing the company's commitment to sustainable and ethical corporate governance. The company achieved an S&P Global Corporate Sustainability Assessment (CSA) score of 81 out of 100, up from 71 the previous year. This inclusion reinforces Laurus Labs’s credibility with global investors.
Read the summary - Low impact
Laurus Labs: Newspaper Publication Regarding Transfer of Shares to IEPF
Laurus Labs Limited published a newspaper notice on May 12, 2026, regarding the transfer of shares to the Investor Education and Protection Fund (IEPF) Authority. This is a regulatory compliance filing.
Read the summary - Low impact
Laurus Labs: Newspaper Publication for TDS on 2nd Interim Dividend FY26
Laurus Labs Limited published newspaper advertisements regarding TDS documents for its 2nd interim dividend for FY 2025-26. The ads appeared on May 07, 2026, in Business Standard and Prajasakti.
Read the summary - Low impact
Laurus Labs Q4 FY26 Earnings Call Transcript Released
Laurus Labs released its Q4 FY26 earnings call transcript. The company reported FY26 revenues of ₹6,813 crore (up 23%) and EBITDA margins of 26.8%. Significant investments are being made in capacity expansion, with ₹3,000 crore planned over the next two years.
Read the summary - High impact
Laurus Labs Q4 FY26 Results: Revenue at ₹3,849 Cr, Profit Before Tax at ₹6,928 Cr
Laurus Labs reported Q4 FY26 consolidated revenue of ₹3,849.38 crore, up from ₹3,643.30 crore YoY. Profit before tax (PBT) was ₹6,928.10 crore. For FY26, consolidated revenue reached ₹1,50,503.77 crore with PBT at ₹26,883.15 crore. Standalone Q4 FY26 revenue was ₹639.59 crore, and PBT was ₹171.71 crore.
Read the summary - Low impact
Laurus Labs Q4 FY26 Results Conference Call Audio Recording Available
Laurus Labs released the audio recording for its Q4 FY26 results conference call, hosted on April 30, 2026. The recording is available via a web link for investors and analysts.
Read the summary - Medium impact
Laurus Labs Appoints Two Independent Directors, One Retires
Laurus Labs appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 2, 2026. Mrs. Aruna Bhinge will retire as an Independent Director on July 6, 2026, after completing her second term. The board meeting concluded on April 30, 2026.
Read the summary - Low impact
Laurus Labs Board Approves Voluntary Closure of German Subsidiary
Laurus Labs' Board approved the voluntary closure of its German subsidiary, Laurus Generics GmbH. The subsidiary had Nil turnover for FY26 and is not material. The closure is not expected to impact Laurus Labs' financials. The Board meeting took place on April 30, 2026.
Read the summary - Medium impact
Laurus Labs to Invest Up to €9.8M in JV KRKA Pharma for New Facility
Laurus Labs will invest up to €9.8 million (approx. ₹87.4 crore) in its joint venture, KRKA Pharma. The co-venturer will invest €10.2 million (approx. ₹90.3 crore). Funds will be used for a new manufacturing facility. The investment is expected by FY27.
Read the summary - Low impact
Laurus Labs Appoints Two Independent Directors, One Director Retires
Laurus Labs appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors, effective July 2, 2026, for five-year terms. Mrs. Aruna Bhinge will retire as an Independent Director on July 6, 2026. The Board approved these changes on April 30, 2026.
Read the summary - Medium impact
Laurus Labs approves 2nd interim dividend of ₹1.20/share for FY26; May 8 set as record date.
Laurus Labs' Board approved a second interim dividend of ₹1.20 per share (60%) for FY25-26. The record date is set for May 08, 2026, with dividend payments expected on or after May 20, 2026. The Board meeting concluded on April 30, 2026.
Read the summary - High impact
Laurus Labs FY26 Revenue ₹6,813 Cr, Up 23%; Net Profit ₹889 Cr, Up 148%
Laurus Labs reported FY26 revenue of ₹6,813 Cr (up 23%) and EBITDA of ₹1,826 Cr (up 64%) with margins at 26.8%. Net profit surged 148% to ₹889 Cr. Q4 FY26 revenue was ₹1,812 Cr (up 5%) with EBITDA at ₹523 Cr. The company declared an interim dividend of ₹1.2 per share.
Read the summary - High impact
Laurus Labs FY26 Revenue Up 23% to ₹6,813 Cr; Profit Surges 148%
Laurus Labs reported FY26 revenue of ₹6,813 Cr, up 23% YoY, driven by CDMO and Affordable Medicines. Net profit surged 148% to ₹889 Cr. Q4 FY26 revenue was ₹1,812 Cr, up 5% YoY. The company announced significant capex for growth projects and an interim dividend of ₹1.20 per share.
Read the summary - Medium impact
Laurus Labs Appoints 2 Independent Directors, Approves JV Investment
Laurus Labs appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors from July 02, 2026. The company approved an investment of up to EUR 9.8 million in its JV, KRKA Pharma, for a new manufacturing facility. Mrs. Aruna Bhinge will retire as Independent Director on July 06, 2026.
Read the summary - Medium impact
Laurus Labs approves FY26 Audited Results, Q4 FY26 Results, and 2nd Interim Dividend of ₹1.20/share
Laurus Labs approved audited financial results for FY26 and Q4 FY26. The company declared a second interim dividend of ₹1.20 per share, with May 8, 2026, as the record date. The 21st AGM is scheduled for July 2, 2026, with a June 25, 2026, e-voting cut-off date.
Read the summary - Medium impact
Laurus Labs Q2 FY26 Results: Profit Up, Interim Dividend Approved
Laurus Labs reported Q2 FY26 results with standalone profit before tax at ₹288.84 crore and consolidated profit before tax at ₹269.73 crore. An interim dividend of ₹0.80 per share was approved for FY26, with a record date of October 31, 2025. The company also addressed past submission discrepancies.
Read the summary - Low impact
Laurus Labs Files SEBI Compliance Certificate for Q4FY26
Laurus Labs Limited submitted a certificate under SEBI regulations for the quarter ended March 31, 2026. The company's Registrar and Share Transfer Agent, KFin Technologies Limited, confirmed that dematerialization/rematerialization details were provided to stock exchanges.
Read the summary - Low impact
Laurus Labs Schedules Q4 & FY26 Earnings Conference Call for April 30, 2026
Laurus Labs will host its Q4 & Full Year FY26 Earnings Conference Call on April 30, 2026, at 5:00 PM IST. The call will discuss the company's financial results. International dial-in details are provided for participation.
Read the summary - Medium impact
Laurus Labs: Unsecured Creditors Approve Composite Scheme of Arrangement
Unsecured creditors of Laurus Synthesis Private Limited and Sriam Labs Private Limited approved the Composite Scheme of Arrangement on April 06, 2026. This follows directions from the Hon’ble NCLT. The scheme remains subject to NCLT and regulatory approvals.
Read the summary - Low impact
Laurus Labs Closes Trading Window from April 1, 2026 for FY26 Results
Laurus Labs Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2026. The board meeting date for approving these results will be announced later.
Read the summary - Medium impact
Laurus Labs Appoints S.R. Batliboi & Associates as New Auditors for 5 Years
Laurus Labs' Board approved appointing S.R. Batliboi & Associates LLP as Statutory Auditors for five years, from 2027 to 2032, pending shareholder approval. The current auditors, Deloitte Haskins & Sells LLP, will complete their term in 2027. The Board meeting concluded on March 12, 2026.
Read the summary - Low impact
Laurus Labs to hold Analyst/Investor Meet in Visakhapatnam on March 18, 2026
Laurus Labs will meet with analysts in Visakhapatnam on March 18, 2026, for a facility visit and management interaction as part of its investor engagement activities. Dates are subject to change, and no UPSI will be shared.
Read the summary - Low impact
Laurus Labs to Participate in Investec India Conference 2026 on March 12-13
Laurus Labs will participate in the Investec India Conference 2026 in Hyderabad from March 12-13, 2026. The company will engage in in-person meetings during the event. No unpublished price sensitive information will be disclosed.
Read the summary - Medium impact
NCLT Approves Composite Scheme of Arrangement for Laurus Labs
Laurus Labs' Composite Scheme of Arrangement approved by NCLT. The scheme involves demerger and amalgamation of subsidiaries. Meetings for unsecured creditors of Laurus Synthesis and Sriam Labs scheduled for April 6, 2026. NCLT dispensed with meetings for equity shareholders and secured creditors of subsidiaries and all stakeholders of Laurus Labs.
Read the summary - Medium impact
Laurus Labs Recognized for Sustainability Leadership by S&P Global
Laurus Labs Limited has been featured in the S&P Global Sustainability Yearbook 2026 for its sustainability leadership. The company achieved an S&P Global CSA score of 81 out of 100 in the pharmaceutical category, an improvement from 71 last year. This recognition places Laurus Labs among the world's most sustainable companies.
Read the summary - Low impact
Laurus Labs gets ESG Score of 68.6/100 for FY25 from SES ESG
Laurus Labs received an ESG Score of 68.6 out of 100 for FY25 from SES ESG Research. The score was assigned independently by SES using publicly available data, without engagement from the company. This information was disclosed on February 20, 2026.
Read the summary - Low impact
Laurus Labs to Participate in 17th Annual Kotak Investor Conference on Feb 24
Laurus Labs will attend the 17th Annual Kotak Investor Conference in Mumbai on February 24, 2026. The company will hold in-person meetings with analysts and institutional investors. No Unpublished Price Sensitive Information will be disclosed during the interactions.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio